{"chief_complaint_en": ["Hematuria", "Weight Loss/Gain"], "content": {"about": {"evidence_based_medicine_en": "", "formula_en": "<p>Risk calculated by combination of above factors.</p>", "more_info_en": "<p><b>Low risk: </b></p> <ul> <li><calculator id='2048'>Gleason Score</calculator> &lt; 6 <b>and</b></li><li>PSA &lt; 10 ng/ml <b>and</b></li><li>Clinical stage T1c or T2a</li></ul> <p><b>Intermediate risk: </b></p><ul><li><calculator id='2048'>Gleason Score</calculator> of 7 <b>or</b></li><li>PSA of 10-20 ng/ml</li><li>Clinical stage T2b</li></ul> <p><b>High risk: </b></p> <ul><li><calculator id='2048'>Gleason Score</calculator> &gt; 8 <b>or</b></li><li>PSA &gt; 20 ng/ml <b>or</b></li><li>Clinical stage T2c or T3</li></ul>", "references_list": {"Original/Primary Reference": [{"href": "http://jama.jamanetwork.com/article.aspx?articleid=187980", "text": "D'Amico AV, Whittington R, Malkowicz S, et al. Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer. JAMA.1998;280(11):969-974. doi:10.1001/jama.280.11.969."}], "Validation": [{"href": "http://www.ncbi.nlm.nih.gov/pubmed/18289596", "text": "Boorjian SA, Karnes RJ, Rangel LJ. Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. J Urol. 2008 Apr;179(4):1354-60; discussion 1360-1. Epub 2008 Mar 4."}, {"href": "http://www.ncbi.nlm.nih.gov/pubmed/18068450", "text": "Hernandez DJ, Nielsen ME, Han M. Contemporary evaluation of the D'amico risk classification of prostate cancer. Urology. 2007 Nov;70(5):931-5."}], "Other References": [{"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328553/", "text": "Rodrigues G, Warde P, Pickles T, et al. Pre-treatment risk stratification of prostate cancer patients: A critical review. Canadian Urological Association Journal. 2012;6(2):121-127. doi:10.5489/cuaj.11085."}, {"href": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1472896/", "text": "Moul JW. The Evolving Definition of Advanced Prostate Cancer. Reviews in Urology. 2004;6(Suppl 8):S10-S17"}]}}, "contributor": {"expert_name": []}, "creator": [{"name": "Dr. Anthony D'Amico", "qa_en": "", "creator_info": {"about_en": "<p>Anthony D'Amico, MD, PhD, is professor of radiation oncology at Harvard Medical School. He is also chief of the Division of Genitourinary Radiation Oncology at Brigham and Women's Hospital and Dana-Farber Cancer Institute. Dr. D'Amico's notable research involves the detection, staging, and treatment of prostate cancer, with over 140 peer-reviewed publications and four co-edited textbooks.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-anthony-d'amico.jpeg", "pubmedLink": "http://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Amico+AV%5BAuthor%5D"}}], "how_to_use": {"pearls_pitfalls_en": "<p>Developed in 1998, estimates risk of prostate cancer recurrence (low, medium or high) from PSA level, <calculator id='2048'>Gleason Score</calculator>, and tumor stage. May be less accurate in men with multiple risk factors.</p>", "use_case_en": "", "why_use_en": ""}, "next_steps": {"advice_en": "<p>With changing treatment patterns, there is a large variation on how to treat different risk groups. Low risk patients seem to do well with many treatment modalities. Intermediate risk patients are a very variable group, where further understanding of risk of cancer \u201cbeyond the gland\u201d may be necessary to guide treatment. High risk groups often do best with a multimodal treatment approach.</p>", "critical_actions_en": "", "management_en": ""}}, "disease_en": ["Cancer"], "favorite_id": 2049, "full_title_en": "D'Amico Risk Classification for Prostate Cancer", "input_schema": [{"label_en": "PSA level", "options": [{"label": "<10 ng/mL", "value": 1}, {"label": "10-20 ng/mL", "value": 2}, {"label": ">20 ng/mL", "value": 3}], "show_points": true, "type": "radio", "name": "psa", "optional": false}, {"label_en": "<calculator id='2048'>Gleason Score</calculator>", "options": [{"label": "\u22646", "value": 1}, {"label": "7", "value": 2}, {"label": "\u22658", "value": 3}], "show_points": true, "type": "radio", "name": "gleason", "optional": false}, {"label_en": "Clinical stage", "options": [{"label": "T1-T2a", "value": 1}, {"label": "T2b", "value": 2}, {"label": "\u2265T2c", "value": 3}], "show_points": true, "type": "radio", "name": "stage", "optional": false}], "instructions_en": "", "medium_description_en": "Assesses 5 year risk of treatment failure based on clinical factors.", "purpose_en": ["Prognosis"], "search_abbreviation_en": ["d'amico", "damico", "dam", "prostate", "CA", "cancer", "oncology", "gleason", "PSA", "t2c", "t3", "t2b", "t1c", "t2a"], "seo": {"meta_description_en": "The D'Amico Risk Classification for Prostate Cancer assesses 5 year failure of treatment based on clinical factors.", "keywords_en": "D'Amico Classification for Recurrence of Prostate Cancer, prostate damico, damico, damico class, damico score, damico prognosis, prostate d\u00e2\u20ac\u2122amico, d\u00e2\u20ac\u2122amico, d\u00e2\u20ac\u2122amico class, d\u00e2\u20ac\u2122amico score, d\u00e2\u20ac\u2122amico prognosis, prostate prognosis, prostate calc, prostate score"}, "short_description_en": "Assesses 5 year failure of prostate CA treatment failure.", "short_title_en": "D'Amico Classification", "slug": "damico-risk-classification-prostate-cancer", "specialty_en": ["Hematology and Oncology", "Urology"], "system_en": ["Urinary", "Oncologic"], "calc_type": "calculator", "dosing": false, "before_use": "", "md5": "11f66df6d7ea6f154e61271133c5d513", "related_calcs": [{"calcId": 2048, "short_title_en": "Gleason Score", "slug": "gleason-score-prostate-cancer"}, {"calcId": 2076, "short_title_en": "Prostate Tumor Volume", "slug": "prostate-tumor-volume-density"}, {"calcId": 10210, "short_title_en": "PREVAIL Model for Prostate Cancer", "slug": "prevail-model-prostate-cancer-survival"}]}